School of Pharmacy, Section of Experimental Medicine, University of Camerino, Via Madonna delle Carceri 9, 62032 Camerino (MC), Italy.
Curr Mol Pharmacol. 2013 Nov;6(3):137-48. doi: 10.2174/187446720603140415215431.
Transient receptor potential (TRP) channels are important candidates mediating Ca(2+) influx in excitable and nonexcitable cells such as normal and neoplastic hematopoietic tissues. They are non selective cation channels implicated in Ca(2+) signaling in hematologic tumor cells. Here, we review the growing experimental evidence indicating that TRP channels should be included among the genes whose expression is altered in hematologic malignancies such as leukemias (AML, ALL, CML and CLL), B- and T-lymphomas and multiple myelomas (MM). These effects depend on the widespread roles played by the TRP channels in the modulation of the proliferation, differentiation and apoptosis of the hematopoietic cells. The analysis of the expression of the different TRP channels belonging to the TRPMs, TRPVs, TRPCs, TRPPs channel families expressed in different hematological malignacies, evidenced a widespread expression of TRPV2 channel in the myeloid and lymphoid leukemias, and a very peculiar expression of this channel in different types of B cell lymphomas and multiple myeloma, that is parallel to the restricted expression of TRPV2 in normal immune cells with respect to its presence in other human tissues. In vivo studies in children AML and ALL patients also evidenced the presence of a genetic polymorphism of the TRPM5 gene, that reduced the risk to develop leukemia in the children. Finally, the coexpression of TRPV5 and TRPV6 channels in lymphocytes, and their involvement in the radioresistance of K562 erythroleukemia cells to ionizing radiation exposure is of more interest. Thus in conclusion, the TRP channels represent promising targets for hematologic cancer therapy, and their exploitation may open to novel pharmaceutical and clinical approaches.
瞬时受体电位 (TRP) 通道是介导包括正常和肿瘤造血组织在内的可兴奋和非兴奋细胞中 Ca(2+) 内流的重要候选者。它们是非选择性阳离子通道,参与血液肿瘤细胞中的 Ca(2+) 信号转导。在这里,我们回顾了越来越多的实验证据,表明 TRP 通道应该被包括在其表达在血液恶性肿瘤(如白血病(AML、ALL、CML 和 CLL)、B 和 T 淋巴瘤和多发性骨髓瘤(MM))中发生改变的基因之列。这些效应取决于 TRP 通道在造血细胞增殖、分化和凋亡的调节中发挥的广泛作用。对属于 TRPMs、TRPVs、TRPCs 和 TRPPs 通道家族的不同 TRP 通道的表达分析表明,TRPV2 通道在髓系和淋巴白血病中广泛表达,并且在不同类型的 B 细胞淋巴瘤和多发性骨髓瘤中这种通道的表达非常特殊,与 TRPV2 在正常免疫细胞中的表达受限相对于其在其他人体组织中的存在平行。在儿童 AML 和 ALL 患者的体内研究也表明了 TRPM5 基因的遗传多态性的存在,这降低了儿童发生白血病的风险。最后,TRPV5 和 TRPV6 通道在淋巴细胞中的共表达及其在 K562 红细胞白血病细胞对电离辐射暴露的放射抗性中的作用更具意义。因此,总之,TRP 通道是血液癌症治疗的有前途的靶点,它们的利用可能为新的药物和临床方法开辟道路。